About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a private company based in Burlington, Massachusetts. It has reported $431,685,720 raised in five offerings on Form D since April 2017. Its chief executive is Peter Lawrence.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 10, 2024 | Jul 24, 2024 | $260,410,720fully sold | 19 | $13.7M | EquityRule 506(b) | Form D ↗ |
| Dec 16, 2022 | Dec 30, 2022 | $17,500,000fully sold | 2 | $8.7M | DebtRule 506(b) | Form D ↗ |
| Oct 19, 2021 | Nov 3, 2021amended Jul 14, 2023 | $128,125,000fully sold | 2 | $64.0M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 5, 2019 | Nov 20, 2019 | $10,000,000fully sold | 2 | $5.0M | DebtRule 506(b) | Form D ↗ |
| Mar 20, 2017 | Apr 4, 2017 | $15,650,000of $22.4M target | 1 | $15.6M | DebtRule 506(b) | Form D ↗ |
| Total, five offerings | $431,685,720 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cardurion Pharmaceuticals's Form D filed Jul 24, 2024.
ER
Evan Rachlin
Director
MM
Michael Mendelsohn
Executive officer and director
DL
Daniel Lynch
Director
ER
Emma Reeve
Director
PL
Peter Lawrence
President and Chief Executive Officer, director
EM
Edward Mathers
Director
AK
Adam Koppel
Director
ND
Nicholas Downing
Director
Earlier filings also listed Kenneth Novack (director, last listed Jul 2023), Keith Gottesdiener (director, last listed Jul 2023) and Amy Schulman (director, last listed Dec 2022).